Those suffering from high blood sugar post COVID-19 can find some relief in ayurvedic formulations like BGR-34 which are based on natural bioactive compounds with dipeptidyl-peptidase-4 (DPP-4) inhibitory effects to manage blood glucose levels. According to experts, a global study published in Diabetes, Obesity and Metabolism Journal found that at least 14.4 per cent of hospitalised patients reported onset of diabetes, causing dysfunctioning of glucose metabolism resulting into hyperglycaemia after recovery.
Though a number of drugs are available to control hyperglycemia, DPP-4 inhibitors have been found to be the safest against post-Covid high blood sugar, according to a recent study in Elsevier journal, they said. Researched by the Council Scientific and Industrial Research-National Botanical Research Institute (CSIR-NBRI) and CIMAP (Central Institute for Medicinal and Aromatic Plants), BGR-34 has natural bioactive compounds of Daruharidra with DPP-4 inhibitory effect.
- Maharashtra reconciles Covid data, India records 3,998 fresh fatalities - July 21, 2021
- COVID-19: Delhi reports 62 cases, 4 deaths - July 21, 2021
- Masked emotions: Infants born during the pandemic - July 21, 2021
- WHO assessing Covaxin data for EUL; Decision date “to be confirmed” - July 20, 2021
- 188 crore Covid vaccine doses required to inoculate 18-plus population: Govt - July 20, 2021
- Delhi reports zero Covid-19 deaths on Sunday, first time since March 2 - July 19, 2021
- HealthTech Startup, Eka.Care raises USD 4.5 mn Seed Funding from Angel and Early-Stage Investors - July 19, 2021
- Is COVID-19 causing new-onset diabetes in children with multisystem inflammatory syndrome? - July 19, 2021
- 40% OF RESPONDENTS HAVE SLEEP DEFICIENCY: REVEALS SURVEY - July 16, 2021
- Bharat Biotech’s partner Ocugen seeks approval for Covaxin in Canada - July 16, 2021